+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycystic ovarian syndrome - Pipeline Insight, 2022

  • ID: 4989316
  • Clinical Trials
  • March 2022
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • AbbVie
  • Bioresearch
  • Cadila healthcare
  • Dexa Medica Group
  • Forendo Pharma
  • Kindex Pharmaceuticals
The publisher’s, “Polycystic ovarian syndrome - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Polycystic ovarian syndrome Understanding


Polycystic ovarian syndrome: Overview

Polycystic Ovarian Syndrome (PCOS) is a condition that affects a woman’s hormone levels. Polycystic Ovarian Syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health and appearance. PCOS is also a common and treatable cause of infertility. Some of the symptoms of PCOS include: Irregular menstrual cycle, too much hair on the face, chin, or parts of the body where men usually have hair, Acne on the face, chest, and upper back, Weight gain or difficulty losing weight, Darkening of skin, particularly along neck creases, in the groin, and underneath breasts. There is no single test to diagnose PCOS. To help diagnose PCOS and rule out other causes of symptoms, medical history and physical exam is evaluated and different tests are performed. There is no cure for PCOS, but the symptoms of PCOS can be managed.

'Polycystic ovarian syndrome - Pipeline Insight, 2022' report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovarian syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovarian syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovarian syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic ovarian syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Polycystic ovarian syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Polycystic ovarian syndrome.

Polycystic ovarian syndrome Emerging Drugs Chapters

This segment of the Polycystic ovarian syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polycystic ovarian syndrome Emerging Drugs


DLBS3233: Dexa Medica

DLBS3233, a new insulin sensitizing agent for Type 2 diabetes, is a combination-bioactive-fraction derived from two herbs, i.e., Lagerstroemia speciosa and Cinnamomum burmannii. Since insulin resistance plays a central pathogenic role in polycystic ovary syndrome (PCOS), DLBS3233 has the potential to benefit women with such a condition, in whom menstrual irregularity, chronic anovulation or infertility are manifested. Dexa Medica completed a phase III clinical trial of DLBS 3233 in women with polycystic ovary syndrome.

Further product details are provided in the report

Polycystic ovarian syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Polycystic ovarian syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Polycystic ovarian syndrome

There are approx. 5+ key companies which are developing the therapies for Polycystic ovarian syndrome. The companies which have their Polycystic ovarian syndrome drug candidates in the most advanced stage, i.e. Phase III include, Dexa Medica.

Phases


The publisher’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration


Polycystic ovarian syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycystic ovarian syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovarian syndrome therapeutic drugs key players involved in developing key drugs.

Polycystic ovarian syndrome Report Insights

  • Polycystic ovarian syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Polycystic ovarian syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Polycystic ovarian syndrome drugs?
  • How many Polycystic ovarian syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovarian syndrome?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovarian syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Polycystic ovarian syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • Bioresearch
  • Cadila healthcare
  • Dexa Medica Group
  • Forendo Pharma
  • Kindex Pharmaceuticals

IntroductionExecutive Summary
Polycystic ovarian syndrome: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

DLBS3233: Dexa Medica
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Mid Stage Products (Phase II)
  • Comparative Analysis

Elagolix: AbbVie
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Early stage products (Phase I/II)
  • Comparative Analysis

Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Inactive Products
  • Comparative Analysis
  • Polycystic ovarian syndrome Key Companies
  • Polycystic ovarian syndrome Key Products
  • Polycystic ovarian syndrome- Unmet Needs
  • Polycystic ovarian syndrome- Market Drivers and Barriers
  • Polycystic ovarian syndrome- Future Perspectives and Conclusion
  • Polycystic ovarian syndrome Analyst Views
  • Polycystic ovarian syndrome Key Companies
  • Appendix

List of Tables
Table 1 Total Products for Polycystic ovarian syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Polycystic ovarian syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Dexa Medica Group
  • AbbVie
  • Kindex Pharmaceuticals
  • Spruce Biosciences
  • Bioresearch
  • Forendo Pharma
  • Cadila healthcare
Note: Product cover images may vary from those shown